Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Downloads
Exports from our negotiations database are available for download in CSV or JSON formats.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Beqvez (fidanacogene elaparvovec)
Status:
Concluded without agreement
Manufacturer:
Pfizer Canada ULC
Indication:
Hemophilia B (congenital Factor IX deficiency) in adults (aged 18 years or older), moderately severe to severe, who are negative for neutralizing antibodies to variant AAV serotype Rh74
Last updated:
April 4, 2025
Status:
Concluded with an LOI
Manufacturer:
Paladin Labs Inc.
Indication:
Epilepsy, partial-onset seizures
Last updated:
March 31, 2025
Status:
Concluded without agreement
Manufacturer:
Pfizer Canada ULC
Indication:
Multiple myeloma, relapsed or refractory, in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy
Last updated:
March 27, 2025
Status:
Concluded with an LOI
Manufacturer:
Astellas Pharma Inc.
Indication:
For the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR)
Last updated:
March 25, 2025
Status:
Concluded with an LOI
Manufacturer:
Fresenius Kabi Canada Ltd.
Indication:
Multiple Indications
Last updated:
March 18, 2025